title: [Trends in the eradication rates of Helicobacter pylori infection in Daegu and Gyeongsangbuk-do, Korea: multicenter study over 13 years].
abstract: OBJECTIVE
  The eradication rates of Helicobacter pylori infection have been reported to have decreased over the years due to antibiotics resistance. The aim of this study is to investigate the trend of eradication rates of first-line triple therapy for H. pylori over the past 13 year period, and to evaluate factors affecting H. pylori eradication in Daegu and Gyeongsangbuk-do, Korea.
  
  
  METHODS
  A total of 2,982 patients with H. pylori infection who were treated with either 1 week or 2 weeks first-line therapy (proton pump inhibitor [PPI], amoxicillin, and clarithromycin) from January 1999 through December 2011 were included in this study. Data were collected by retrospectively reviewing the medical records.
  
  
  RESULTS
  The overall H. pylori eradication rate was 87.2%. The eradication rates from 1999 to 2011 fluctuated between 78.0% and 95.7%, but no definite evidence of a decreasing tendency was seen over the 13 year period (p=0.113). Furthermore, there was no significant difference in the eradication rate according to the duration of therapy (p=0.592). However, there was a significant difference in the eradication rate among various PPIs (p<0.01).
  
  
  CONCLUSIONS
  There was no decreasing trend in the H. pylori eradication rate over the past 13 years in Daegu and Gyeongsangbuk-do, Korea. There also was no difference in the eradication rates depending on duration of therapy. However, a significant difference was noted among various PPIs.
authors.affiliation: Division of Gastroenterology and Hepatology, Department of Internal Medicine, Yeungnam University College of Medicine, 170 Hyeonchung-ro, Nam-gu, Daegu 705-717, Korea.
authors.forename: Yeoun Su
authors.initials: YS
authors.lastname: Jung
authors.forename: Si Hyung
authors.initials: SH
authors.lastname: Lee
authors.forename: Chan Seo
authors.initials: CS
authors.lastname: Park
authors.forename: Myung Jin
authors.initials: MJ
authors.lastname: Oh
authors.forename: Kyeong Ok
authors.initials: KO
authors.lastname: Kim
authors.forename: Byung Ik
authors.initials: BI
authors.lastname: Jang
authors.forename: Seong Woo
authors.initials: SW
authors.lastname: Jeon
authors.forename: Min Kyu
authors.initials: MK
authors.lastname: Jung
authors.forename: Kyung Sik
authors.initials: KS
authors.lastname: Park
authors.forename: Eun Soo
authors.initials: ES
authors.lastname: Kim
authors.forename: Kwang Bum
authors.initials: KB
authors.lastname: Cho
authors.forename: Jin Tae
authors.initials: JT
authors.lastname: Jung
authors.forename: Joong Goo
authors.initials: JG
authors.lastname: Kwon
authors.forename: Eun Young
authors.initials: EY
authors.lastname: Kim
authors.forename: Wan Jung
authors.initials: WJ
authors.lastname: Kim
authors.forename: Chang Heon
authors.initials: CH
authors.lastname: Yang
mesh_terms: D000328:Adult; D000368:Aged; D000658:Amoxicillin / Q000627:therapeutic use; D000900:Anti-Bacterial Agents / Q000627:therapeutic use*; D017291:Clarithromycin / Q000627:therapeutic use; D060740:Disease Eradication / Q000639:trends*; D004334:Drug Administration Schedule; D004359:Drug Therapy, Combination; D016099:Endoscopy, Gastrointestinal; D064098:Esomeprazole / Q000627:therapeutic use; D005260:Female; D016481:Helicobacter Infections / Q000188:drug therapy* / Q000473:pathology; D016480:Helicobacter pylori; D006801:Humans; D016015:Logistic Models; D008297:Male; D008875:Middle Aged; D009853:Omeprazole / Q000627:therapeutic use; D054328:Proton Pump Inhibitors / Q000627:therapeutic use*; D064750:Rabeprazole / Q000627:therapeutic use; D056910:Republic of Korea; D012189:Retrospective Studies; D016896:Treatment Outcome
chemical_list: D000900:Anti-Bacterial Agents; D054328:Proton Pump Inhibitors; D064750:Rabeprazole; D000658:Amoxicillin; D017291:Clarithromycin; D009853:Omeprazole; D064098:Esomeprazole